Physician profile
Thomas L Miller
NPI 1326048802
$1,765.11
in general payments reported to CMS, 2019-2025
29 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.57 · 2020: $145 · 2021: $351 · 2022: $343 · 2023: $268 · 2024: $126 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.60 | 2021-2024 | |
| Novo Nordisk INC | $204.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $143.40 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $132.97 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.91 | 2025 | Caplyta |
| Pfizer INC. | $90.26 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.56 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.91 | 2020-2022 | |
| Astellas Pharma US INC | $64.78 | 2020-2024 | Veozah |
| Exact Sciences Corporation | $59.64 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $58.31 | 2022 | |
| Amgen INC. | $56.10 | 2019-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $55.87 | 2020-2023 | Xarelto |
| Amarin Pharma, INC. | $44.41 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.83 | 2024-2025 | Breztri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.16 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.18 | 2021-2022 | |
| Abbott Laboratories | $29.80 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $25.44 | 2019-2020 | |
| Dexcom, INC. | $19.59 | 2024 | Dexcom G6 Transmitter |
| Dermira, INC. | $19.15 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.32 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.80 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2022 | |
| Allergan, INC. | $12.69 | 2020 | |
| Merck Sharp & Dohme LLC | $12.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.73 | 2022 | |
| Therapeuticsmd, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.